BehaviorNCT01343472
Evaluation of the Washington Intensive Supervision Program
A study testing WISP supervision and Parole-as-usual in people with Behavior and Drug Users, run by Pepperdine University at 1 site in United States.
Trial summary
This study entails an evaluation of the Washington Intensive Supervision Program (WISP). The purpose of the evaluation is to test whether subjects assigned to WISP perform better than those assigned to parole-as-usual (PAU). Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Behavior, Drug Users
- What is being tested?
- WISP supervision and Parole-as-usual
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2011to Jun 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Inmates released by DOC to community corrections supervision
- Supervised out of the Seattle CJC (Community Justice Center) to include field offices and offenders from the downtown "Metro" unit, Southeast Seattle unit, Northgate (north Seattle) and West Seattle.
- Have a parole supervision discharge date at least one year from the date of release from entry into WISP
Who cannot join
- Level III Sex Offenders
- Existing assignment to supervision that precludes WISP. These include: Drug Offender Sentencing Alternative (DOSA)and Special Sex Offender Sentencing Alternative (SSOSA).
- Dangerously Mentally Ill (DMIO)
Trial locations and contacts
1 site in 1 country.
United States1 site
Seattle Community Justice Center
Seattle, Washington
About this study
This study entails an evaluation of the Washington Intensive Supervision Program (WISP). The purpose of the evaluation is to test whether subjects assigned to WISP perform better than those assigned to parole-as-usual (PAU).
Read the detailed description
This study entails an evaluation of the Washington Intensive Supervision Program (WISP). WISP is a program targeting high-risk parolees in Seattle, and is modeled after the HOPE program in Hawaii. The purpose of the evaluation is to test whether subjects assigned to WISP perform better than those assigned to parole-as-usual (PAU) on a number of outcomes, including drug use, missed appointments, recidivism, prison and jail stays, and parole revocations. WISP uses regular random drug testing and close community supervision, paired with swift and certain, but modest sanctions for every detected violation.
- Conditions
- Behavior, Drug Users
- Being tested
- WISP supervision, Parole-as-usual
- Keywords
- Behavior, Drug users
- Medical subject headings
- Behavior, Drug Misuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WISP supervisionBehavioural
Also called HOPE supervision
WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
Parole-as-usualBehavioural
Also called PAU
Parolees are supervised under standard parole supervision practice in Washington State.
| Study group | Role | What they receive |
|---|---|---|
| WISP supervision | Experimental | Parolee supervised under WISP parole model. Receives: Behavioral: WISP supervision |
| Parole-as-usual | Active comparator | Parolees supervised under Washington State's parole-as-usual Receives: Behavioral: Parole-as-usual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Revocation rate
Percentage of subjects in each condition who are revoked from parole and returned to prison
Measured: 12 months
Secondary outcomes (5)
% positive drug tests
Percentage of random and scheduled drug tests that test positive for illicit drugs
Measured: 12 months
Days incarcerated
Total number of days incarcerated in jail or prison
Measured: 12 months
% Missed appointments
Percentage of parole appointments that are missed.
Measured: 12 months
New arrests
Number of new arrests.
Measured: 12 months
Assessed risk
Parolee risk assessment (high, medium, low)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2011 (estimated)
- Study startJan 2011
- Primary completionJan 2012
- Study completionJun 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BehaviorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pepperdine University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Brett T. Leach, Pepperdine University
- Investigators
- Angela Hawken, PHD, Principal investigator, Pepperdine University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01343472
- Sponsor's protocol ID
- SPP0311F08
- Status last verified
- Apr 2018
- First submitted
- 26 Apr 2011
- Last updated
- 10 Apr 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Washington Intensive Supervision Program
- ClinicalTrials.gov ID
- NCT01343472
- Acronym / sponsor ID
- SPP0311F08
- Conditions
- Behavior, Drug Users
- Keywords
- Behavior, Drug users
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Pepperdine UniversityUniversity, hospital or other
- Study start
- Jan 2011
- Primary completion
- Jan 2012 (actual)
- Study completion
- Jun 2012 (actual)
- First posted
- 28 Apr 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study entails an evaluation of the Washington Intensive Supervision Program (WISP). The purpose of the evaluation is to test whether subjects assigned to WISP perform better than those assigned to parole-as-usual (PAU).
Detailed description
This study entails an evaluation of the Washington Intensive Supervision Program (WISP). WISP is a program targeting high-risk parolees in Seattle, and is modeled after the HOPE program in Hawaii. The purpose of the evaluation is to test whether subjects assigned to WISP perform better than those assigned to parole-as-usual (PAU) on a number of outcomes, including drug use, missed appointments, recidivism, prison and jail stays, and parole revocations. WISP uses regular random drug testing and close community supervision, paired with swift and certain, but modest sanctions for every detected violation.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| WISP supervision | Experimental | Behavioral: WISP supervisionParolee supervised under WISP parole model. |
| Parole-as-usual | Active comparator | Behavioral: Parole-as-usualParolees supervised under Washington State's parole-as-usual |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Inmates released by DOC to community corrections supervision
- Supervised out of the Seattle CJC (Community Justice Center) to include field offices and offenders from the downtown "Metro" unit, Southeast Seattle unit, Northgate (north Seattle) and West Seattle.
- Have a parole supervision discharge date at least one year from the date of release from entry into WISP
Key exclusion criteria (3 listed)
- Level III Sex Offenders
- Existing assignment to supervision that precludes WISP. These include: Drug Offender Sentencing Alternative (DOSA)and Special Sex Offender Sentencing Alternative (SSOSA).
- Dangerously Mentally Ill (DMIO)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WISP supervisionAlso: HOPE supervisionWISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing. | Behavioural | WISP supervision |
| Parole-as-usualAlso: PAUParolees are supervised under standard parole supervision practice in Washington State. | Behavioural | Parole-as-usual |
Primary outcome
Revocation rate
Time frame: 12 months
Percentage of subjects in each condition who are revoked from parole and returned to prison
5 secondary outcomes
% positive drug tests
Time frame: 12 months
Days incarcerated
Time frame: 12 months
% Missed appointments
Time frame: 12 months
New arrests
Time frame: 12 months
Assessed risk
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2018.
Related trials for Behavior
Not yet recruitingObservational study
Validation of Wearable Core Body Temperature-Based Circadian Rhythm Digital Biomarkers
Mood Disorders, Major Depressive Diorder
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Active, not recruiting
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
Human Papilloma Virus (HPV) Vaccine
RecruitingObservational study
Development and Validation of Learning and Decision-Making Tasks
Normal Physiology
Not yet recruitingEarly Phase 1
Causal Mechanisms of Odor-Guided Behavior in Humans
Normal Physiology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angela Hawken, PHD principal investigator
Pepperdine University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WISP supervision and Parole-as-usual in people with Behavior and Drug Users, run by Pepperdine University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Revocation rate (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2018.